Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.53 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.51 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.51 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.48 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.48 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.48 |
| ▸ | PRKCA | P17252 | 2/20 | 0.47 |
| ▸ | PRKCD | Q05655 | 2/20 | 0.47 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.46 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.46 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3485036 | 0.84 | KMT2A (0.56) | KMT2ASMN1; SMN2L3MBTL1LMNAMAOB | |
| SCHEMBL2381049 | 0.82 | KMT2A (0.60) | KMT2ASMN1; SMN2MAOBALOX5NR4A2 | |
| SCHEMBL6366231 | 0.81 | L3MBTL1 (0.52) | L3MBTL1TSHRMAPK1TDP1 | |
| SCHEMBL6366230 | 0.81 | L3MBTL1 (0.52) | L3MBTL1TSHRMAPK1TDP1 | |
| SCHEMBL15232861 | 0.81 | KMT2A (0.59) | KMT2ASMN1; SMN2MAOBALOX5NR4A2 | |
| SCHEMBL5379536 | 0.81 | KMT2A (0.53) | KMT2ASMN1; SMN2L3MBTL1LMNAMAOB | |
| SCHEMBL4951331 | 0.81 | KMT2A (0.53) | KMT2ASMN1; SMN2L3MBTL1LMNAMAOB | |
| SCHEMBL6366936 | 0.80 | HPGD (0.55) | KMT2ASMN1; SMN2MEN1 | |
| SCHEMBL5811954 | 0.79 | MMP8 (0.54) | KMT2ALMNAMEN1 | |
| SCHEMBL10635430 | 0.79 | MMP8 (0.54) | KMT2ALMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2018-09-25 | — | — | US | disclosed |
| EP-3079687-B1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO LTD (KR) | 2018-02-28 | — | — | EP | disclosed |
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2016-10-27 | — | — | US | disclosed |
| EP-3079687-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | Bio-Pharm Solutions Co., Ltd. (KR) | 2016-10-19 | — | — | EP | disclosed |
| WO-2015088272-A9 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-10-01 | — | — | WO | disclosed |
| WO-2015088272-A1 | SULFAMATE DERIVATIVE COMPOUNDS FOR USE IN TREATING OR ALLEVIATING PAIN | BIO-PHARM SOLUTIONS CO., LTD. (KR) | 2015-06-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160311792-A1 | Sulfamate Derivative Compounds for Use in Treating or Alleviating Pain | SULT2A1, SULT1A1, TRPV1 | KMT2A 1146/4885SMN1; SMN2 465/4885L3MBTL1 4778/4885 |
| US-10081615-B2 | Sulfamate derivative compounds for use in treating or alleviating pain | SULT2A1, SULT1A1, TRPV1 | KMT2A 1146/4885SMN1; SMN2 465/4885L3MBTL1 4778/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.